Advertisement
Device Sectors
Subscribe to Device Sectors
View Sample

FREE Email Newsletter

Grants fund projects that will tackle ‘Grand Challenges'

December 17, 2010 2:33 pm | by Arizona State University | News | Comments

ASU engineering faculty will lead projects to address some of the world's most critical problems with support from the Grand Challenges Research Seed Funding programread more

Accuray Establishes Medical Affairs Function

December 17, 2010 9:33 am | by Bio-Medicine.Org | News | Comments

SUNNYVALE, Calif., Dec. 17, 2010 /- Accuray Incorporated (Nasdaq: ARAY ), a global leader in the field of radiosurgery, announced today that the company has established a Medical Affairs function to accelerate CyberKnife data collection, utilization and referral patterns and to provide...

Boston researchers test treatment for autism link

December 17, 2010 9:32 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Children's Hospital Boston scientists have initiated a three-year clinical trial to test a potential treatment for Rett Syndrome, known to cause autism in girls.

Advertisement

VIDEO From Siemens and Synaptic Digital: Not Your Father's X-Ray Machine

December 17, 2010 8:32 am | by Bio-Medicine.Org | News | Comments

NEW YORK, Dec. 17, 2010 /- Say so-long to the days of black and white 2-D X-rays and images. From CT, to MRI and PET, medical imaging is faster, more detailed, and three-dimensional and is revolutionizing the way medicine is practiced.  Thanks to years of improved imaging, today's...

An ITG Majestic Market Research Study Indicates a Bright Future for Gilenya, Despite Concerns About Its Safety

December 17, 2010 7:31 am | by Bio-Medicine.Org | News | Comments

NEW YORK, Dec. 17, 2010 /- A study published this week by ITG (NYSE: ITG ) revealed that Novartis recently approved drug, Gilenya, has already taken share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year.  ...

BG Medicine backs out of IPO

December 17, 2010 6:31 am | by Mass High Tech: The Journal of New England Technology | News | Comments

On the cusp of going public, BG Medicine Inc. has pulled its IPO, Dow Jones reports. BG, which is developing a cardiac diagnostic test, initially filed to go public in January with plans for an $86.3 million offering before scaling back twice prior to pulling the plug.

Cardinal Health Receives Regulatory Clearance for Kinray Acquisition

December 17, 2010 6:31 am | by Bio-Medicine.Org | News | Comments

DUBLIN, Ohio, Dec. 17, 2010 /- Cardinal Health today announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for its proposed acquisition of Kinray, Inc., a leading pharmaceutical...

Call for speakers to present at IQPC's MEDCon, the Medical Electronic Device Conference and Expo

December 17, 2010 5:36 am | by MEDCon | News | Comments

The Medical Electronic Device Conference & Expo (MEDCon), being held May 16 - 18, 2011 at Navy Pier in Chicago focuses on specific needs of electrical and design engineers for medical devices.

Advertisement

Beetroot juice could help people live more active lives

December 17, 2010 5:31 am | by EurekAlert | News | Comments

(University of Exeter) New research into the health benefits of beetroot juice suggests it's not only athletes who can benefit from its performance enhancing properties -- its physiological effects could help the elderly or people with heart or lung-conditions enjoy more active lives.

The high price of sleep disorders

December 17, 2010 5:30 am | by EurekAlert | News | Comments

(University of Copenhagen) Danish sleep researchers at the University of Copenhagen and the Danish Institute for Health Services Research have examined the socio-economic consequences of the sleep disorder hypersomnia in one of the largest studies of its kind. The sleep disorder has...

Drug Combinations That May Cause Major Drug Interactions Common Among Seniors Who Take Antidepressants, According to Thomson Reuters Research

December 17, 2010 2:31 am | by Bio-Medicine.Org | News | Comments

ANN ARBOR, Mich., Dec. 17, 2010 /- More than half of older Americans who were prescribed antidepressants for the first time were already taking a medication that could adversely interact with the antidepressant , according to a new study from Thomson Reuters. For one-fourth of the seniors...

Non-Profit Breastcancer.org Shares Concerns with FDA on Avastin Breast Cancer Recommendation

December 16, 2010 8:32 pm | by Bio-Medicine.Org | News | Comments

ARDMORE, Pa., Dec. 16, 2010 /PRNewswire-USNewswire/ -- Dr. Marisa Weiss, president and founder of Breastcancer.org and a breast oncologist in the Philadelphia area submitted a letter to the U.S. Food and Drug Administration prior to the Oncology Drug Advisory Committee (ODAC) meeting to...

U.S. FDA Approves Second Bayer Oral Contraceptive That Also Raises Folate Levels

December 16, 2010 4:36 pm | by Bio-Medicine.Org | News | Comments

WAYNE, N.J., Dec. 16, 2010 /- Bayer HealthCare Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), SAFYRAL™ (drospirenone 3 mg/ ethinyl estradiol 30 mcg/ levomefolate calcium 451 mcg tablets and levomefolate...

Advertisement

Zimmer Holdings to Present at 29th Annual J.P. Morgan Healthcare Conference

December 16, 2010 4:35 pm | by Bio-Medicine.Org | News | Comments

WARSAW, Ind., Dec. 16, 2010 /- Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a global leader in musculoskeletal care, announced that it will be participating in the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on January 10, 2011, at 12 p.m. Eastern Time. A...

Avastin (bevacizumab): Process for Removal of Breast Cancer Indication Begun(2)

December 16, 2010 2:31 pm | by U.S. Food & Drug Administration | News | Comments

FDA recommending removing the breast cancer indication for Avastin because the drug has not been shown to be safe and effective for that use.

Microban International Announces Breakthrough in Antimicrobial Technologies for Medical Devices

December 16, 2010 9:36 am | by Bio-Medicine.Org | News | Comments

HUNTERSVILLE, N.C., Dec. 16, 2010 /- Hospital Acquired Infections (HAI's) are a serious health threat associated with over 100,000 deaths each year.  These secondary infections following surgery are a major contributor to increased healthcare costs; experts estimate they add in...

Improvements in Recurrence-Free Survival in Early Stages of Colorectal Cancer Will Limit Growth of Drug Treatment Opportunities for Advanced Disease

December 16, 2010 9:35 am | by Bio-Medicine.Org | News | Comments

BURLINGTON, Mass., Dec. 16, 2010 /- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that projected improvements in recurrence-free survival in early stages of colorectal cancer is the most important factor limiting...

FDA Begins Process To Remove Breast Cancer Indication From Avastin Label

December 16, 2010 9:35 am | by Bio-Medicine.Org | News | Comments

SILVER SPRING, Md., Dec. 16, 2010 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration announced today that the agency is recommending removing the breast cancer indication from the label for Avastin (bevacizumab) because the drug has not been shown to be safe and effective...

Fenwal Receives FDA Clearance for Wireless Data Export on ALYX Blood-Collection System

December 16, 2010 9:35 am | by Bio-Medicine.Org | News | Comments

LAKE ZURICH, Ill., Dec. 16, 2010 /- Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance to market its ALYX™ component...

Beaumont Hospital Launches Study of Single-Dose Radiation Treatment for Prostate Cancer

December 16, 2010 9:34 am | by Bio-Medicine.Org | News | Comments

ROYAL OAK, Mich., Dec. 16, 2010 /- Beaumont Hospital radiation oncologists have launched a research study to treat men with low to intermediate risk prostate cancer with a single dose of radiation. Alvaro Martinez, M.D., FACR, professor and chair, Oakland University William Beaumont...

Solta Medical Ships One Millionth Tip for Thermage and Fraxel Devices

December 16, 2010 6:32 am | by Bio-Medicine.Org | News | Comments

HAYWARD, Calif., Dec. 16, 2010 /- Solta Medical, Inc. (Nasdaq: SLTM ), the pioneer in fractional resurfacing and non-invasive skin tightening and a market leader in aesthetic skin treatments, today announced it has shipped its one millionth tip for the revolutionary Thermage and Fraxel...

ERT Unveils Full Range of ePRO Solutions Providing the Power of Choice for Clinical Trial Sponsors

December 16, 2010 6:31 am | by RealWire | News | Comments

PHILADELPHIA, PA, 16 December 2010 ERT, a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries, today announced the launch of its comprehensive suite of electronic patient-reported outcome (ePRO) solutions. As the ePRO market...

NOVAVAX Receives FDA Clearance to Launch Phase I RSV Vaccine Clinical Trial

December 16, 2010 5:31 am | by Bio-Medicine.Org | News | Comments

ROCKVILLE, Md., Dec. 16, 2010 /- Novavax, Inc. (Nasdaq: NVAX ) announced today that the company's Phase I clinical trial to evaluate a new vaccine candidate to prevent respiratory syncytial virus (RSV) infection has been cleared by the U.S. Food and Drug Administration (FDA) and is no...

FDA Safety Notification: Risk of Eye and Skin Injuries from High-powered, Hand-held Lasers Used for Pointing or Entertainment

December 16, 2010 5:30 am | by U.S. Food & Drug Administration | News | Comments

The FDA is alerting consumers about the risk of eye and skin injuries from exposure to high-powered laser pointers. FDA regulations limit the energy output of hand-held laser pointers to 5 milliwatts (mW).

First NxStage® Home Hemodialysis Patients Celebrate Seven-Year Anniversary

December 16, 2010 4:32 am | by Bio-Medicine.Org | News | Comments

LAWRENCE, Mass., Dec. 16, 2010 /- NxStage Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer of innovative dialysis products, today announced that a group of its first patients are celebrating their seven-year anniversary of home hemodialysis treatment with the NxStage® System...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading